Based on the strong evidence supporting the involvement of PI3K/AKT signaling in fibrotic processes, PI3K inhibitors are currently under clinical evaluation for the treatment of IPF and myelofibrosis (Wang et al., 2022; Zhao et al., 2022). Here, AKT1 is linked to idiopathic pulmonary fibrosis.